TNFRSF10A and neoplasm: In pancreatic CSCs, JNK inhibition allows the decrease in DcR1 via an IL-8-dependent autocrine process, while DR4/5 expression is increased, thereby sensitising cells to TRAIL treatment.187 Consequently, the authors observed diminished tumour burden and number of CTCs.